**Evaluation of outcome measures**

#  A -Total Y-BOCS scores on CBT, sertraline and combined treatment; observed case analysis and intent to treat analysis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | Study Arm |  | Difference between Arms  |  | Adjusted difference (ITT) |
|  | All | CBT | Sertraline | Combined |  | CBT vs Sertraline | CBT vs Combined | Sertraline vs Combined |  | CBT vs Sertraline | CBT vs Combined | Sertraline vs Combined |
| Baseline | 49 | 16 | 15 | 18 |  |  |  |  |  |  |  |  |
|  | 26.7 (5.9) | 26.6 (7.1) | 26.5 (5.2) | 27.0 (5.6) |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Week 8 | 35 | 12 | 9 | 14 |  | -0.56 (-7.9 , 6.8) | .24 (-5.7 , 6.3) | .79 (-7.7 , 6.1) |  | .8 (-5.1 , 6.7) | 2.0 (-1.8 , 5.7) | 1.2 (-5.0 , 7.4) |
|  | 20.7 (7.5) | 20.7 (7.5) | 21.2 (8.6) | 20.4 (7.3) | d’ | -0.07 (-.80 , .90) | .03 (-.74 , .80) | .10 (-.74 , .94) |  | .1 (-.6 , 1.1) | .25 (-.5 , 1.0) | .15 (-.7 , 1.0) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Week 16 | 29 | 9 | 7 | 13 |  | 2.5 (-7.6 , 12.7) | 3.1 (-4.0 , 10.3) | .6 (-10.3 , 9.1) |  | 3.8 (-.45 , 12.2) | 4.3 (0.0 ,8.6) | .05 (-8.3 , 9.3) |
|  | 18.4 (8.9) | 20.6 (6.8) | 18.1 (12.0) | 17.5 (8.7) | d’ | .27 (-.73 , 1.3) | .39 (-.47 , 1.24) | .06 (-.86 , .98) |  | .42 (-.6 , 1.4) | .55 (-.3 , 1.4) | .05 (-.9 , 1.0) |
| Week 32 | 22 | 8 | 6 | 8 |  | 5.1 (-5.3 - 15.5) | -.13 (-8.6 - 8.4) | -5.3 (-7.2 - 17.7) |  | 4.9 (-3.4 , 13.3) | .3 (-6.2 , 6.7) | -4.6 (-13.0 , 3.7) |
|  | 17.0 (9.1) | 18.6 (5.8) | 13.5 (11.9) | 18.8 (9.6) | d’ | .57 (-.52 , 1.7) | -.02 (-1.0 , .96) | -.49 (-1.6 , .59) |  | .55 (-.5 , 1.7) | .04 (-.9 , 1.1) | -.43 (-1.5 , .7) |
| Week 52 | 23 | 8 | 6 | 9 |  | 6.0 (-6.7 - 18.7) | 1.5 (-9.4 - 12.5) | -4.5 (-7.1 - 16.1) |  | 5.1 (-5.1 , 15.2) | 1.2 (-7.5 , 10.0) | -3.8 (-12.7 , 5.0) |
|  | 15.3 (10.3) | 17.5 (11.1) | 11.5 (10.3) | 16.0 (10.1) | d’ | .56 (-.53 , 1.6) | .14 (-.81 , 1.1) | -.44 (-1.5 , .61) |  | .47 (-.6 , 1.5) | .12 (-.8 , 1.1) | -.37 (-1.4 , .7) |

On the left hand side of the table, the numbers of randomised patients completing each rating point of the study are listed in the row above, and mean total Y-BOCS (SD) listed below.

The middle columns of the table, the mean between-arm differences (CI) are listed together with the effect size (CI) (below) calculated as Cohen’s *d*. An effect size >.3 is marked in bold**.**

The right hand side of the table presents the ITT analysis, reporting adjusted mean group differences, and associated effect size.